Laboratory Investigation

Kidney International (1992) 42, 46–55; doi:10.1038/ki.1992.259

Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure

Yoshihiko Kakinuma1, Tetsuya Kawamura1, Teresa Bills1, Toshimasa Yoshioka1, Iekuni Ichikawa1 and Agnes Fogo1

1Departments of Pediatrics and Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence: Yoshihiko Kakinuma MD, Division of Pediatric Nephrology, C-4204 Medical Center North, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2584, USA

Received 1 May 1991; Revised 13 January 1992; Accepted 20 February 1992.

Top

Abstract

Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Previous studies in experimental models of progressive renal failure have shown that the capacity of antihypertensive drugs to protect glomeruli from sclerosis is often unpredictable from their effect on systemic blood pressure. The present study was undertaken to ascertain whether this systemic blood pressure-independent structure-preserving effect of antihypertensives, particularly angiotensin II converting enzyme inhibitors (ACEI), is confined to the glomerulus or not, as well as whether this effect is mediated via angiotensin II (Ang II). The following experimental drug regimens were used in the rat model of subtotal nephrectomy (sNPX): so-called triple therapy [TRX; a combination of reserpine 5 mg/liter drinking water (DW), hydralazine 80 mg/liter DW and hydrochlorothiazide 25 mg/liter DW], or ACEI (either captopril, CPL, 600 mg/liter DW, enalapril, ENL, 400 mg/liter DW or lisinopril, LSL, 200 mg/liter DW), or a novel Ang II receptor antagonist (Ang IIR, L-158,809, 20 mg/liter DW). These dosages were identified in pilot studies to be the minimum required to control systemic blood pressure in the early phase up to 12 weeks. In addition, a separate group was treated with a higher dose of L-158,809 (80 mg/liter DW) with equipotent systemic pressor effect. Treatment was initiated eight weeks after subtotal nephrectomy following renal biopsy, and animals were sacrificed at 16 weeks. In ACEI treated rats, carotid arterial wall thickening (WT), defined as ratio of media thickening to radius of outer vessel wall, was similar to normal age-matched control (0.073 in all ACEI treated rats, vs. 0.074 in normal control) and significantly less than with TRX (ratio 0.118) or untreated sNPX (0.130). Even more remarkably, coronary arteriole WT in ACEI-treated rats averaged 0.139, a value less than one half and one third of TRX (0.298) and untreated sNPX control (0.388), respectively. Similar results were obtained for mesenteric artery WT. These findings were closely paralleled by changes of glomerular sclerosis. In untreated sNPX control rats, glomerular sclerosis increased from biopsy to autopsy specimens by an average of 458%. Although TRX dampened the degree of increase in sclerosis to on average 212%, this protective effect was far less than that achieved by ACEI. In the latter, sclerosis increased on average only 65% from biopsy to autopsy. Although all ACEIs were more effective than TRX, captopril and lisinopril groups showed greatest benefit at these doses. Ang IIR also protected renal and extrarenal structures with 34% increase of sclerosis index in low dose and WT 0.088, 0.117 and 0.112, respectively in carotid, mesenteric and coronary arteries. Higher dose had greater protective effects, although systemic pressures were comparable to the low dose. The findings indicate that in minimum dosages required for controlling systemic blood pressures ACEI and Ang IIR are more potent than other vasodilators in protecting glomerular structure. This greater structure-preserving potency of ACEI and Ang IIR is not limited to the glomerulus, but extends to other systemic vascular beds, where variable lesions also develop in chronic renal failure. The similar results with Ang IIR and ACEI further indicate that the progressive morphological damage of glomerular and extraglomerular vasculatures in chronic renal failure involves local action of angiotensin II.

Top

References

  1. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82:322–330, 1988 | PubMed | ISI | ChemPort |
  2. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kindey Int 36:626–635, 1989
  3. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on the glomerular mesangial lesion. Kidney Int 40:195–202, 1991 | PubMed | ISI | ChemPort |
  4. Anderson S, Brennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000, 1986 | PubMed | ISI | ChemPort |
  5. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925–1930, 1986 | PubMed | ISI | ChemPort |
  6. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526–536, 1989 | PubMed | ISI | ChemPort |
  7. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757–1768, 1988 | PubMed | ISI | ChemPort |
  8. Brunner FP, Thiel G, Hemle M, Bock HA, Mihatsch MJ: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 36:969–977, 1989 | PubMed | ChemPort |
  9. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612–619, 1985 | PubMed | ISI | ChemPort |
  10. Owens GK: Influence of blood pressure on development of aortic medical smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 9:178–187, 1987 | PubMed | ISI | ChemPort |
  11. Linz W, Schølkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 11:1325–1350, 1989 | ISI | ChemPort |
  12. Canby CA, Tomanek RJ: Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 257:H1110–H1118, 1989
  13. Clozel JP, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 7:267–275, 1989
  14. Wang DH, Prewitt RL: Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 15:68–77, 1990 | PubMed | ISI | ChemPort |
  15. Brunner HR, Kirshman JD, Sealey JE, Laragh JH: Hypertension of renal origin: Evidence for two different mechanisms. Science 174:1344–1346, 1971
  16. Akahoshi M, Carretero OA: Body fluid volume and angiotensin II in maintenance of one-kidney, one clip hypertension. Hypertension 14:269–273, 1989
  17. Clozel JP, Kuhn H, Hefti F: Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med 87(Suppl 6B):92S–95S, 1989 | Article |
  18. Powell JS, Clozel JP, Müller RKM, Kuhn H, Hefti F, Hosang M, Baumgartne HR: Inhibitions of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186–188, 1989 | Article | PubMed | ISI | ChemPort |
  19. Prescott MF, Webb RL, Reidy MA: Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Am J Pathol 139:1291–1296, 1991 | PubMed | ISI | ChemPort |
  20. Rambausek M, Ritz E, Mall G, Mehls O, Katus H: Myocardiac hypertrophy in rats with renal insufficiency. Kidney Int 28:775–782, 1985 | PubMed | ISI | ChemPort |
  21. Oken DE: Does the ultrafiltration coefficient play a key role in regulating glomerular filtration in the rat. Am J Physiol 25:F505–F515, 1989
  22. Pfeffer JM, Pfeffer MA, Fröhlich ED: Validity of an indirect tail-cuff method for determining systolic arterial pressure in anesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 78:957–962, 1971 | PubMed | ISI | ChemPort |
  23. Cushman DW, Wang FL, Fung WC, Grover GJ, Harvey CM, Acalese RJ, Mitch SL, Deforrest JM: Comparison in vitro, ex vivo and in vivo of the action of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharamacol 28:115S–131S, 1989
  24. Chang RSL, Siegl PKS, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ: In vitro pharmacology of a highly potent and selective nonpeptide angiotensin II (AII) receptor antagonist: L-158,809. (abstract) FASEB J 5 (Part III):6993, 1991
  25. Mantlo NB, Chakravarty PK, Ondeyka D, Chen A, Camara VJ, Chang RSL, Lotti VJ, Siegl PKS, Patchett AA, Greenlee WJ: Potent, orally active imidazo[4,5-b]pyridine angiotensin II receptor antagonists. J Med Chem 34:2919–2922, 1991
  26. Siegl PKS, Chang RS, Greenlee WJ, Lotti VJ, Mantlo NB, Patchett AA, Swaet CS: In vivo pharmacology of a highly potent and selective nonpeptide angiotensin II (AII) receptor antagonist: L-158,809. (abstract) FASEB J 5 (Part III):6994, 1991
  27. Ichikawa I, Maddox DA, Cogan MG, Brenner BM: Dynamics of glomerular ultrafiltration in euvolemic Munich-Wistar rats. Renal Physiol 1:121–131, 1978
  28. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int 26:137–143, 1984 | PubMed | ISI | ChemPort |
  29. Führ J, Kazmarczyk J, Krüttgen CD: Eine einfache colorimetrishe Methode zur Inulinbestimmung für Nieren-clearance-untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33:729–730, 1955 | PubMed | ISI | ChemPort |
  30. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 47:1–9, 1980 | PubMed | ISI | ChemPort |
  31. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P: Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 65:1G–7G, 1990
  32. Levy BI, Michel JB, Salzmann JL, Azizi M, Poitevin P, Safar M, Camilleri JP: Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 63:227–239, 1988 | PubMed |
  33. Ryan JW, Ryan US, Schultz DR, Whitaker C, Chung A, Dorer FE: Subcellular localization of pulmonary angiotensin converting enzyme (kininase II). Biochem J 146:497–499, 1975 | PubMed | ChemPort |
  34. Caldwell PRB, Seegal BC, Hsu KC: Angiotensin converting enzyme: Vascular endothelial 1 localization. Science 191:1050–1051, 1976 | PubMed | ChemPort |
  35. Ody C, Junod AF: Converting enzyme activity in endothelial cells isolated from pig pulmonary artery and aorta. Am J Physiol 232:C95–C98, 1977
  36. Miyazaki M, Okunishi H, Nishimura K, Toda N: Vascular angiotensin converting enzyme activity in man and other species. Clin Sci 66:39–45, 1984 | PubMed | ChemPort |
  37. Dzau VJ, Gibbons GH: Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension. Am J Cardiol 60:99I–103I, 1987
  38. Re RN: Cellular mechanisms of growth in cardiovascular tissue. Am J Cardiol 60:104I–109I, 1987
  39. Seikaly MG, Arant BS Jr, Seney FD Jr: Endogenous angiotensin concentrations in specific intrarenal compartments of the rat. J Clin Invest 86:1352–1357, 1990 | PubMed | ISI | ChemPort |
  40. Homma T, Hoover RL, Ichikawa I, Harris RC: Angiotensin II induces hypertrophy and stimulates collagen production in cultured rat mesangial cell. (abstract) Clin Res 38:358A, 1990
  41. Taubman MB, Berk BC, Izumo S, Tsuda T, Alexander RW, Nadal-Ginard B: Angiotensin II induces c-fos mRNA in aortic smooth muscle. J Biol Chem 264:526–530, 1989 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT